Cardlytics, Inc. (CDLX)
Cardlytics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Cardlytics, Inc. (CDLX) is a Advertising Agencies company based in US with a market capitalization of $40M. Revenue declined 16.2% year-over-year and the company generated $8.8M in free cash flow. This page tracks CDLX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 440 employees · IPO Feb 9, 2018
Valuation
Valuation & price
$0.63 · as of May 17, 2026 · -98.0% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
—
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$40M
Market cap
-16.2%
Revenue growth (YoY)
45.0%
Gross margin
$8.8M
Free cash flow (USD)
$166.6M
Net debt
9.8%
Share dilution
0/4
Graham criteria passed
Defensive-investor screen
Communication Services
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 7, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
Questions
Frequently asked questions
What is Cardlytics, Inc.'s market cap?
Cardlytics, Inc. (CDLX) has a market capitalization of $40M.
What is CDLX's P/E ratio?
A meaningful P/E ratio is not available for CDLX — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
Are insiders buying CDLX stock?
SEC Form 4 filings show no open-market insider buys at Cardlytics, Inc. in the last 90 days (0 sells).
Same arena
Related companies in Advertising Agencies
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.